Skip to main content
Download PDF

Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial

Trials volume 17, Article number: 142 (2016) Cite this article

Abstract

Background

Severe pneumonia (SP) is a major complication of respiratory system diseases that is associated with high mortality and morbidity. If not treated correctly, it may rapidly lead to sepsis and multiple organ dysfunction syndrome. Despite continuous developments in antibiotic treatments for SP, the mortality rate remains high. Both basic and clinical research show that Xuebijing injection (XBJ) can improve the symptoms of SP. The aim of this study is to evaluate the effectiveness and safety of XBJ compared with placebo.

Methods/design

This multicenter, blinded, randomized controlled trial will be conducted with a total of 700 participants with SP. Using a central randomization system, participants will be randomized (1:1) into groups receiving either XBJ or placebo (within 24 h of diagnosis of SP) for 5–7 days with a 28-day follow-up. All participants will receive conventional treatment simultaneously. Both XBJ and placebo will be administered using a photophobic infusion set to avoid bias. The primary outcome is improvement of Pneumonia Severity Index risk rate. Adverse events will be monitored throughout the trial.

Discussion

This is the first and largest randomized trial done in China on SP treatment using a Chinese herbal extract. In this trial, we will use central randomization and an electronic case report form, and we have designed an innovative blinding method for the traditional Chinese medicine injection. The results of this trial may help to provide evidence-based recommendations to clinicians for treatment of SP.

Trial registration

Chinese Clinical Trials Registry ChiCTR-TRC-13003534. Registered 24 June 2013.

Peer Review reports

Background

Severe pneumonia (SP) is one of the leading causes of death in patients in the intensive care unit (ICU) [1]. The average mortality in hospitalized patients with SP is between 15 % and 30 %, with a mortality rate of between 50 % and 60 % in the ICU [2, 3]; thus, patients with SP represent a major concern for physicians [4, 5]. If not treated properly, SP may eventually lead to complications that include multiple organ dysfunction syndrome (MODS) and sepsis, which is characterized by persistent inflammation [6], and ultimately death.

Clinical and basic research have revealed that SP is associated with bacterial or viral infections. In response to invasion by pathogenic microorganisms, sustained release of inflammatory mediators leads to systemic inflammatory response syndrome (SIRS) and coagulopathy [7, 8]. Therefore, in addition to active and early treatment for pathogenic microorganisms using antibiotics, anti-inflammatory and anticoagulant therapy may improve the prognosis of patients with SP. Currently, the main therapeutic strategy for SP involves administration of antibiotics and anti-inflammatory agents [9]. However, long-term antibiotic therapy not only increases the risk of antibiotic resistance but also produces liver and kidney toxicity and other side effects [10]. Moreover, previous anti-inflammatory strategies showed limited efficacy in clinical trials, in part because they targeted single cytokines [11]. Compared with Western medicine, traditional Chinese medicine (TCM) has been shown in recent studies to have promising results for the treatment of SP [12, 13], indicating that, used in complementary and alternative therapies, TCM may represent a novel therapeutic approach for SP.

Wang Jinda, a founder of emergency medicine in China, proposed that integrative medicine therapy can raise the cure rate in acute critical disease [14]. He summarized four rules for four syndromes of intensive and critical care based on prescriptions of a toxin-resolving, blood-quickening decoction (解毒活血汤) and house of blood-expelling decoction (血府逐瘀汤) described by Wang Qingren, a famous physician of the Qing dynasty [8]. Through pharmacodynamic screening, he developed the Xuebijing (XBJ) injection [15], a formula composed of five medicinal herbs. Safflower (hong hua) acts as the sovereign drug, activating blood circulation and removing blood stasis, while red peony root (chi shao) and Ligusticum wallichii (chuang xiong) function as the minister drug, cooling blood, dispersing blood stasis, and detoxifying and magnifying the effects of the sovereign drug to activate blood and move qi. Salvia miltiorrhiza (dan shen) and Angelica sinensis (dang gui) are assistants which enrich blood and disperse stasis.

In the TCM perspective, the basic pathogenesis of SP is blood stasis and toxicity blockade. XBJ, a Chinese patent medicine for the symptomatic treatment of SP, has the effect of promoting blood circulation and removing blood stasis, as well as mediating fever attenuation and detoxification. The main components of XBJ are hydroxysafflor yellow A, paeoniflorin, ferulic acid, and salvianolic acid B. Basic research has confirmed that XBJ functions as an endotoxin antagonist, an anti-inflammatory agent, and an anticoagulant and that it regulates immune function [16–19]. Previous clinical studies showed that routine medication combined with XBJ may reduce infection indicators and the levels of inflammatory cytokines induced by SP [20]. The present clinical study is associated with limitations of sample size, clinical treatment time, and nonuniform drug dosage, as well as with inconsistencies in inclusion and exclusion criteria. Therefore, a large-scale, multicenter, blinded, randomized clinical trial (RCT) is required to confirm the efficacy and safety of XBJ injection for the treatment of SP.

The aim of this trial is to evaluate the effectiveness and safety of XBJ injection for SP in China by comparison with a placebo.

Methods/design

Research type

We are conducting a randomized, controlled, blinded, multicenter trial.

Study setting

The hospitals enrolled in this study are all tertiary referral medical centers, including 28 Western medicine hospitals and 2 TCM hospitals. All of these hospitals are listed in Table 1.

Table 1 Research settings and name of each ethics committee
Full size table

Study criteria

The patients enrolled in this study should meet the diagnostic and inclusion criteria and provide written informed consent.

Diagnostic criteria

The diagnostic criteria we will use for SP are based on the Infectious Diseases Society of America/American Thoracic Society guidelines [21]. The criteria for SIRS are based on the 1991 Chicago meeting standards [22].

Inclusion criteria

The inclusion criteria are as follows:

  1. 1.

    Age ≥18 years and ≤75 years, male or female

  2. 2.

    Weight ≥40 kg and ≤100 kg

  3. 3.

    Meet the diagnostic criteria for SP

  4. 4.

    Meet the diagnostic criteria for SIRS

  5. 5.

    Provide signed informed consent

Exclusion criteria

The exclusion criteria are as follows:

  1. 1.

    Diagnosis of SP for more than 48 h

  2. 2.

    Pregnant and lactating women

  3. 3.

    Disorders likely to have serious effects on survival of the primary disease (such as unresectable tumors, blood diseases, prolonged bed rest caused by cerebrovascular diseases, Alzheimer’s disease, or HIV)

  4. 4.

    Using immunosuppressants, hormones (a cumulative total methylprednisolone dose ≥1500 mg), and/or using cytotoxic drugs within the previous 6 months, or using all of these drug types within the previous 7 days

  5. 5.

    Pneumonitis, interstitial pulmonary fibrosis, alveolar proteinosis, and allergic alveolitis induced by obstructive lung tumors

  6. 6.

    Psychiatric patients

  7. 7.

    Allergies (to two or more substance allergies)

  8. 8.

    Participation in other clinical trials in the previous 30 days

  9. 9.

    Using prohibited drugs in the 7 days before enrollment

  10. 10.

    Patients diagnosed with severe acute respiratory distress syndrome [23]

  11. 11.

    Patients who were unsuitable for participation in this trial or unable to complete the follow-up according to the judgment of the investigators

Other criteria

Forbidden and concomitant drugs

The following criteria apply to forbidden and concomitant drugs:

  1. 1.

    Use of prohibited medicines, including ulinastatin as well as TCM injections with efficacy similar to that of XBJ, such as Tanreqing and Reduning

  2. 2.

    Details of any additional drugs or therapy must be recorded in the case report form (CRF), including the drug name, dose, and treatment duration

Suspension criteria

The criteria for suspension of participation are as follows:

  1. 1.

    Poor compliance of investigators or patients

  2. 2.

    Occurrence of serious adverse events (AEs), complications, or fatal physiological changes

  3. 3.

    Using forbidden medications or treatments during the trial that might affect analysis of the results

  4. 4.

    Voluntary withdrawal

  5. 5.

    Incomplete data

  6. 6.

    Withdrawal for various reasons, such as death or failure to attend follow-up visits

Interventions

Methods of administration

The treatment group receives routine medication [24] plus XBJ injection (specification 10 ml/piece, packaging 10 pieces/container). The control (placebo) group receives routine medication plus a 0.9 % sodium chloride injection. The dosage and speed of injection for the placebo are identical to the XBJ injection (100 ml twice daily, intravenous drip for more than 80 minutes).

Routine medications for SP

The routine medications used in this trial for SP are as follows:

  1. 1.

    Types of antibiotics: A β-lactam (cefotaxime, ceftriaxone, or ampicillin/sulbactam) plus either a macrolide (azithromycin, clarithromycin, or erythromycin) or a fluoroquinolone (for penicillin-allergic patients, a respiratory fluoroquinolone and aztreonam); for Pseudomonas infection, a β-lactam (piperacillin/tazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin; or the above β-lactam plus an aminoglycoside and an antipneumococcal fluoroquinolone (for penicillin-allergic patients, substitute aztreonam for the above β-lactam)

  2. 2.

    Dosage of hormones: Using hormones is one of our exclusion criteria; however, during the intervention period (5–7 days), low-dose ( 1 mg/kg/day), methylprednisolone can be given if necessary

Dispensing and combination methods

The dispensing and combination methods used in this trial are as follows:

  1. 1.

    XBJ (100 ml) is diluted to 200 ml using saline as a solvent.

  2. 2.

    The use of other injections simultaneously during the course of intravenous infusions is prohibited.

  3. 3.

    Other injections should be separated by injection of 50 ml of saline.

Precautions

The precautions we will observe are as follows:

  1. 1.

    Patients receive the study drug within 24 h of enrollment.

  2. 2.

    The routine treatment of SP (e.g., antibiotics, hormones, anticoagulants, vasopressors) should be carried out simultaneously and XBJ injection should not be used as a substitute.

Sample size

Previous studies [25, 26] showed that the improvement of PSI risk rating of the control group is 70 %. Assuming that the improvement in the treatment group is 10 % higher than that in the control group, the sample size is calculated according to the parameters α = 0.05 (two-sided test) and β = 0.2. Using PASS 11 software (NCSS Statistical Software, Kaysville, UT, USA), we calculated that 291 patients should be recruited into each group. Considering an attrition rate of no more than 15 %, the eligible participants in each group should be no fewer than 342. Therefore, we determined that we would need a sample size of 350 in each group (n = 700).

Randomization

The randomization of the trial will be completed at an independent data center using a central randomization system to achieve dynamic minimization randomization. When a subcenter accepts an eligible participant, researchers will log into the central randomization system to enter stratified factor information of the patient, including age, mechanical ventilation condition, and the source of infection (community- or hospital-acquired infection). The central randomization system will then assign an identification code and a random number unique to this participant, who then will receive the corresponding treatment regimen.

Blinding

Blinding methods

The blinding methods used in this trial are as follows:

  1. 1.

    Investigators and drug administrators have independent authority to log into the central randomization system. The investigators are responsible for screening subjects, obtaining informed consent, entering patients’ information into the system, and obtaining a random number; however, the patients’ group assignment is concealed. After the subjects are randomly assigned by the investigators, drug administrators will log into the system to obtain the patient’s group with the random number and assign the study drugs to subjects.

  2. 2.

    Both the XBJ and placebo are administered using the photophobic infusion set to avoid the subjects’ ascertaining their group assignment.

  3. 3.

    Both the paper and electronic CRFs are filled in with the patient’s random number only, while details of the group information are not included.

  4. 4.

    During the course of the study, investigators and drug administrators work relatively independently, both having signed a confidentiality agreement that prohibits any disclosure of group-related information.

  5. 5.

    Unblinding is divided into two processes by the interactive web response system (IWRS) central randomization system. First, after data-locking, the random numbers corresponding to the group code (e.g., A group, B group) are revealed. Second, when the statistical report is fixed, the actual group will be revealed.

Emergency unblinding

If knowledge of the patient’s group is required in the event of an emergency or a requirement for rescue, researchers first obtain details of the patient’s group from the drug administrators, then the reason for the unblinding will be reported to the major investigators within 24 h. The subjects are withdrawn from the study after unblinding. Detailed unblinding cause, date, treatment situation, and results will be reported in the CRF and signed by the administrator.

Content and points of data capture

The content and points of data capture in the trial are as follows:

  1. 1.

    Screening period (1 day): 24 h before recruitment

  2. 2.

    Intervention period (5–7 days): follow-up every day and recorded

  3. 3.

    Period after intervention (within 28 days after treatment): follow-up at day 8 and day 28

Different items are measured according to the time points of data collection. The details are shown in Table 2.

Table 2 Content and points of data capture
Full size table

Outcome measures

Primary outcome measures

The primary outcome of this trial is the improvement of the PSI risk rating [27]. The evaluation criteria are as follows:

  1. 1.

    Significantly effective: the risk rating decreases two levels

  2. 2.

    Effective: the risk rating decreases one level

  3. 3.

    Ineffective: no change or deterioration in the risk rating

Evaluation of improvement in PSI risk rating is the sum of the total numbers of significantly effective and effective divided by the total number, multiplied by 100 %.

Secondary outcome measures

The secondary outcome measures are as follows:

  1. 1.

    SIRS improvement: determined according to changes in the SIRS diagnostic indicators [28] before and after the intervention. These evaluation criteria are as follows:

    1. a.

      Significantly effective: the symptoms improved (three or four diagnostic indicators change from abnormal to normal)

    2. b.

      Effective: the symptoms were relieved (two diagnostic indicators change from abnormal to normal)

    3. c.

      Ineffective: no change or deterioration in the symptoms (only one diagnostic indicator changes from abnormal to normal, or other condition)

    4. d.

      SIRS improvement degree is measured as the sum of the total numbers of significantly effective and effective divided by the total number, multiplied 100 %

  2. 2.

    Lung Injury Score (LIS) improvement: only for patients with ventilation; the evaluation criteria are based on those defined by Murray and colleagues [29] according to the changes in LIS before and after the intervention (Table 3), measured as LIS improvement degree equals the sum of significantly, moderately, and slightly effective divided by the total number, multiplied by 100 %

  3. 3.

    The highest body temperature

  4. 4.

    MODS score [30, 31] improvement according to the differences in MODS scores before and after the intervention:

    1. a.

      Significantly effective: MODS score decrease ≥7

    2. b.

      Moderately effective: MODS score decrease 4–6

    3. c.

      Slightly effective: MODS score decrease 2–3

    4. d.

      Ineffective: no change or increase in MODS score

    5. e.

      MODS score improvement degree is measured as the sum of significantly, moderately, and slightly effective divided by the total number, multiplied by 100 %

  5. 5.

    Acute Physiology and Chronic Health Evaluation II (APACHE II) [32] score improvement according to the differences in the APACHE II scores before and after the intervention using the lowest APACHE II score within 24 h (≤19, low risk; ≥20, high risk)

  6. 6.

    Sequential Organ Failure Assessment [33] score improvement assessed according to the number of organ failures (0–1 organ failure, low risk; ≥2 organ failures, high risk)

  7. 7.

    The changes in inflammation and coagulation indicators: C-reactive protein, procalcitonin, and d-dimer

  8. 8.

    Chest x-ray changes

  9. 9.

    The mutual conversion rates of invasive mechanical ventilation and noninvasive mechanical ventilation

  10. 10.

    Mortality rate after 28 days

  11. 11.

    The time of mechanical ventilation, total duration of ICU stay, hospitalization, and antibiotic use

  12. 12.

    The time of bacterial cultures becoming negative

Table 3 Evaluation criteria of Lung Injury Score improvement
Full size table

Safety outcomes

Safety outcomes, including vital signs, routine blood and urine tests, fecal occult blood test, hepatic (alanine transaminase, aspartate transaminase, serum total bilirubin) and renal (blood urea nitrogen, creatinine) function, coagulation index (fibrinogen, prothrombin time, activated partial thromboplastin time), electrocardiogram results, and AEs. All of these indicators will be monitored closely throughout the trial.

Adverse events

Every AE occurring during the study must be recorded in the AE form according to the actual circumstances. The following information should be recorded: occurrence time, severity, duration, adopted measure, and the outcome of the AE. The number and rate of AEs and serious AEs of the two groups are recorded. A crossover table is used to describe the changes in laboratory and electrocardiogram indicators.

Statistical analysis

The statistical analysis will be performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). Rates of PSI improvement between the groups will be analyzed by performing superiority tests. If the lower limit of the 95 % confidence interval is larger than a clinically meaningful difference, therapeutic effects of the experimental group are deemed to be clinically and statistically better than those of the control group. Two-sided tests will be performed for all the other statistical analyses. Cochran-Mantel-Haenszel χ2 tests or Fisher’s exact tests will be used for comparison of categorical outcomes. Continuous outcomes will be analyzed by using Student’s t test. p values ˂0.05 are considered to indicate statistical significance.

Data management

Data input

Two data input media will be applied in this study. Researchers add patient information to the paper CRF promptly and synchronously with input into the electronic CRF. The occurrence of unexpected problems during this process should be recorded, and the data management center will be informed in a timely manner.

Data verification

In this trial, Oracle Clinical (OC) software (Oracle Corp., Redwood Shores, CA, USA) will be used for centralized data management [34]. Modifications made by clinical investigators will be checked promptly, and the results will be reported to the researchers and clinical research associates (CRAs). The CRAs are responsible for verifying the consistency and accuracy of the paper and electronic CRFs and for reporting the results to the clinical investigators.

Data lockup

Data lockup will be implemented by data management on completion of the study. Researchers are unable to modify data subsequently, and problems will modified in the statistical analysis.

Quality assurance

Compliance control

Before the trial, caution will be applied in selection of the participating institutions and investigators. All the participating institutions will be required to have approval from the drug clinical trial agency, and all the investigators will be required to be qualified in the implementation of Good Clinical Practice (GCP) training according to the State Food and Drug Administration (SFDA). Before the trial, investigators will receive rigorous training and take a comprehensive examination to improve compliance [35]. In the CRF, the investigators will be required to provide authentic and reliable data of combined medication and AE conditions; the subjects will be required to comply with their medication regimen and receive follow-up in accordance with the trial plan; and the drug administrator will ensure accurate recording of the dosage and amount of drug remaining to monitor patient compliance.

Monitoring and inspection

Both online monitoring and in situ supervision will be used in this trial. With the support of the “check” function in the OC software, large-scale clinical trial dynamic management will be implemented to ensure that the data are collected completely, promptly, and accurately. The organizer will nominate monitors for regular visits to each unit for reexamination of the CRF to ensure consistency with the original data.

Ethical issues

Ethics statement

Researchers are responsible for ensuring that the study is conducted in accordance with the principles of the Declaration of Helsinki and GCP. Participants entirely voluntarily give their written informed consent before any study procedures, and they can voluntarily withdraw from the study for any reason. Parents or guardians are informed of the risks and benefits of the study if the participants have difficulty with decision-making. Each patient will be identified with a unique random number, and the private data must be preserved by researchers to maintain confidentiality.

Ethical approval

The study protocol, informed consent form (ICF), and other research documents were approved by the medical ethics committee of Zhongshan Hospital, Fudan University [approval registration number 2011-38(3)]. Other participating agencies were approved by the medical ethics committee of each hospital. (The names of all ethics committees that approved our study in every center are listed in Table 1.)

Clinical trial insurance

Before the trial, “safe clinical trial insurance” was purchased from Ping An Insurance Group (China) (policy number 10330001900105798721).

Informed consent form

The ICF must be signed by the participants or their representatives, and the date must be included. The signed ICF will be preserved by researchers and participants independently. The ICF preserved by the researchers will be made available to project managers for monitoring, auditing, and inspection.

Discussion

XBJ is a confidential National Technology Product approved by the Ministry of National Science and Technology and the State Secrecy Bureau, and is authorized as a patented product by the State Intellectual Property Office (patent protection period of 20 years). In 2004, XBJ was approved for marketing by the SFDA (number Z20040033). Preliminary clinical trial [36] results indicated that routine medication combined with XBJ can significantly reduce the death rate due to SP, and can also decrease the duration of mechanical ventilation and antibiotic use, with no adverse reactions such as liver and kidney dysfunction.

Blinding methods

Due to the characteristically colored liquid resulting from the TCM injection production process [37], it is difficult to produce a placebo with a similar appearance; therefore, most previous clinical trials have not been blinded in design. Such unblinded trials are subject to risks of selection bias and evaluation bias. To overcome this issue, we used photophobic infusion sets to implement a blinded design for the present study. Furthermore, this trial was designed with the aid of computer technology, using an updated version of the conventional processes of the central IWRS randomization system to conceal group information. Investigators and drug administrators will be given independent authority to log into this system following signing of a confidentiality agreement. All these methods were used to ensure that the blinded design is implemented and maintained for the duration of the present study.

Strict randomization was implemented to minimize selection bias and evaluation bias. Furthermore, the use of the photophobic infusion set not only ensured that the blinded design of this trial was maintained but also avoided the placebo effect, rendering the research findings fair and objective. To our knowledge, the blinding and randomization methods used are being adopted in TCM injection clinical studies for the first time. These strategies can be used to overcome the difficulties associated with the blinded design of such studies, and also to investigate feasible approaches to clinical evaluation of other colored agents.

Outcome measures

In this trial, we selected improvement in PSI risk rating as the primary outcome. PSI risk rating is used to classify patients with pneumonia into 5 grades of increased risk for short-term mortality on the basis of 20 variables that are routinely available at presentation [38]. This risk rating precisely reflects the condition of patients with pneumonia [38]. It has been extensively validated in prospective and retrospective studies and is widely used in hospitals [39–41]. The secondary outcomes of this trial include several severity-of-illness scoring systems, such as LIS, MODS, and APACHE II, which reflect the condition of patients with SP from different perspectives and are predictive of patient mortality. Most previously reported SP trials used mortality or length of ICU stay as primary outcomes. However, many types of drugs and devices are used to treat patients in ICUs; therefore, it is difficult to establish a significant impact of a novel therapy on mortality among ICU patients. Consequently, in this study, selected indicators were used to reflect the condition of patients and to determine the significance of the therapy.

Safety of XBJ injection

The TCM injection is a new formulation of Chinese herbs based on a modification of the oral delivery of the traditional decoction. This alternative is characterized by rapid and efficient delivery and provides more choice for the clinical treatment of disease. However, there is little experience with TCM injections in the clinic; consequently, the safety of this formulation remains to be confirmed, and incorrect administration may be associated with AEs. Therefore, TCM injections must be used cautiously. Confirmation of the safety of XBJ injection as a TCM is of paramount importance. A meta-analysis of the efficacy and safety of XBJ injection [42] revealed that no AEs occurred in 1022 patients who received this treatment, indicating that XBJ injection is safe. There are also some reports of the AEs associated with XBJ injection [43], the majority of which occurred in patients receiving XBJ for the first time. Of the instances of AEs, 58.8 % occurred within 30 minutes of the injection, 64.7 % were caused by improper use of XBJ, and 47.1 % were recorded among patients with a history of allergies; all the patients improved after drug withdrawal.

In this trial, we also selected inflammation and coagulation index as well as hepatic and renal function as safety outcomes. All of these indicators will be closely monitored throughout the trial to determine the long-term safety of XBJ.

Strengths and limitations

This is a first large-sample, multicenter, blind RCT of TCM injection and was designed on the basis of previous studies. We adopted the central randomization system, electronic CRF, and other advanced systems and achieved innovative breakthroughs in the blinded design. The high standards for selection of the participating institutions and researchers, rigorous training of researchers, and the implementation process for inspection and other quality control methods were designed to ensure the quality of this trial. Ethical approval, signed informed consent, and clinical trial insurance coverage fully protect the interests of the subjects. We selected several severity-of-illness scoring systems as primary and secondary outcomes for objective evaluation the effects of XBJ. Throughout the trial, safety outcomes will be closely monitored to avoid AEs and crossover tables will be used to describe the changes in laboratory and electrocardiogram indicators. However, due to the large sample, the time of participant recruitment is long. The season and climate change may influence the prognosis of disease. The results of the trial remain to be confirmed in clinical research practice.

Trial status

Currently, participant recruitment is ongoing.

Abbreviations

AE:

adverse event

APACHE:

Acute Physiology and Chronic Health Evaluation

CRA:

clinical research associate

CRF:

case report form

CT:

computed tomography

GCP:

Good Clinical Practice

ICF:

informed consent form

ICU:

intensive care unit

IWRS:

interactive web response system

LIS:

Lung Injury Score

MODS:

multiple organ dysfunction syndrome

OC:

Oracle Clinical software

PSI:

Pneumonia Severity Index

RCT:

randomized clinical trial

SFDA:

State Food and Drug Administration

SIRS:

systemic inflammatory response syndrome

SP:

severe pneumonia

TCM:

traditional Chinese medicine

XBJ:

Xuebijing

References

  1. Sirvent JM, de la Torre MC, Lorencio C, Taché A, Ferri C, Garcia-Gil J, et al. Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24 h of ICU admission. Med Intensiva. 2013;37:308–15.

    Article  CAS  PubMed  Google Scholar 

  2. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.

    Article  CAS  PubMed  Google Scholar 

  4. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133:610–7.

    Article  PubMed  Google Scholar 

  5. World Health Organization (WHO). The top 10 causes of death. Fact Sheet 310 [updated May 2014]. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 12 March 2016.

  6. Hagiwara S, Iwasaka H, Hasegawa A, Hidaka S, Uno A, Ueo K, et al. Filtration leukocytapheresis therapy ameliorates lipopolysaccharide-induced systemic inflammation in a rat model. J Surg Res. 2011;171:777–82.

    Article  CAS  PubMed  Google Scholar 

  7. Matsuse H, Yanagihara K, Mukae H, Tanaka K, Nakazato M, Kohno S. Association of plasma neutrophil elastase levels with other inflammatory mediators and clinical features in adult patients with moderate and severe pneumonia. Respir Med. 2007;101:1521–8.

    Article  PubMed  Google Scholar 

  8. Levi M, van der Poll T, Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med. 2012;70:114–20.

    CAS  PubMed  Google Scholar 

  9. De Pascale G, Bello G, Tumbarello M, Antonelli M. Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the literature. Curr Opin Pulm Med. 2012;18:213–21.

    Article  PubMed  Google Scholar 

  10. Ariani F, Liu K, Jing Z, Qu J. Glucocorticosteroid in treatment of severe pneumonia. Mediators Inflamm. 2013;2013:865635. doi:10.1155/2013/865635.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ulloa L, Tracey KJ. The “cytokine profile”: a code for sepsis. Trends Mol Med. 2005;11:56–63.

    Article  CAS  PubMed  Google Scholar 

  12. Torres-Rosas R, Yehia G, Peña G, Mishra P, del Rocio T-BM, Moreno-Eutimio MA, et al. Dopamine mediates the vagal modulation of the immune system by electroacupuncture. Nat Med. 2014;20:291–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang Y, Ji M, Wang L, Chen L, Li J. Xuebijing injection improves the respiratory function in rabbits with oleic acid-induced acute lung injury by inhibiting IL-6 expression and promoting IL-10 expression at the protein and mRNA levels. Exp Ther Med. 2014;8:1593–8.

    PubMed  PubMed Central  Google Scholar 

  14. Wang J. Integrative treatment of acute critical illness diagnosis and treatment ideas and practice course. Tianjin J Tradit Chin Med. 1998;15:241–2.

    Google Scholar 

  15. Xue L. Research of the new strategy for the treatment of systemic inflammatory response syndrome and multiple organ dysfunction syndrome: an experimental study of the effect of traditional Chinese herb “xue bi jing.”. Chin Crit Care Med. 1997;9:18–20. 64.

    Google Scholar 

  16. Jiao L, Yao Y, Shou S. Effects of Xuebijing injection on hepatic gelsolin and inflammatory cytokine in septic rats. Med J Chin Peoples Liberation Army. 2011;36:14–6.

    Google Scholar 

  17. He XD, Wang Y, Wu Q, Wang HX, Chen ZD, Zheng RS, et al. Xuebijing protects rats from sepsis challenged with Acinetobacter baumannii by promoting annexin A1 expression and inhibiting proinflammatory cytokines secretion. Evid Based Complement Alternat Med. 2013;2013:804940. doi:10.1155/2013/804940.

    PubMed  PubMed Central  Google Scholar 

  18. Geng P, Xia P, Gu J, Xu M, Xu J, Tan D, et al. Intervention of Xuebijing injection against early hypercoagulability in patients with severe sepsis. Chin J Integr Tradit West Med Intensive Crit Care. 2008;15:346–9.

    Google Scholar 

  19. Dai XG, Yao YM, Ai YH, Yu Y. The enhancing effect of “Xuebijing injection” on lipopolysaccharide-induced apoptosis of regulatory T cells and mediation of polarization of helper T cells [in Chinese]. Zhonghua Shao Shang Za Zhi. 2009;25:106–10.

    CAS  PubMed  Google Scholar 

  20. Zhu MJ, Zhang G, Hu MH, Chen YB, Ji CL. Stasis-resolving and detoxifying effect of Xuebijing injection on severe pneumonia: a systematic review. Chin J Evid Based Med. 2014;14:462–8.

    Google Scholar 

  21. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27–72.

    Article  CAS  PubMed  Google Scholar 

  22. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644–55.

    Article  CAS  PubMed  Google Scholar 

  23. The ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–33.

    Google Scholar 

  24. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39:165–228.

    Article  CAS  PubMed  Google Scholar 

  25. Julián-Jiménez A, Reyes MJ P de l, Parejo Miguez R, Laín-Terés N, Cuena-Boy R, Lozano-Ancín A. Improved management of community-acquired pneumonia in the emergency department. Arch Bronconeumol. 2013;49:230–40.

    Article  PubMed  Google Scholar 

  26. Li J, Qiao Y, Zhang H, et al. The therapeutic effects of Xuebijing injection on community acquired pneumonia patients accompanied by acute kidney injury. Chin J Integr Tradit West Med Intensive Crit Care. 2012;19(4):226–9.

    Google Scholar 

  27. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138–80.

    Article  CAS  PubMed  Google Scholar 

  28. Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022–33.

    Article  CAS  PubMed  Google Scholar 

  29. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720–3.

    Article  CAS  PubMed  Google Scholar 

  30. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638–52.

    Article  CAS  PubMed  Google Scholar 

  31. Middleton PM. Practical use of the Glasgow Coma Scale: a comprehensive narrative review of GCS methodology. Australas Emerg Nurs J. 2012;15:170–83.

    Article  PubMed  Google Scholar 

  32. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.

    Article  CAS  PubMed  Google Scholar 

  33. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001;286:1754–8.

    Article  CAS  PubMed  Google Scholar 

  34. Oracle Corporation. Oracle Clinical. http://www.oracle.com/us/products/applications/health-sciences/e-clinical/clinical/index.html. Accessed 12 March 2016.

  35. Shang HC, Zhang JH, Dai GH, Cao HB, Ren M, Xiang YZ, et al. Administration and quality control of large-scale clinical trials of traditional Chinese medicine [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2007;5:1–4.

    Article  PubMed  Google Scholar 

  36. Song Y, Song Z, Jiang J, Bai C. Clinical efficacy and safety evaluation of Xuebijing on severe pneumonia. Int J Respir. 2012;32(22):1692–5.

    Google Scholar 

  37. Food S, Administration D. National Drug Standards (amendment) promulgated pieces. Drug Stand China. 2013;14:448–73.

    Google Scholar 

  38. Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis. 2007;44:41–9.

    Article  PubMed  Google Scholar 

  39. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.

    Article  CAS  PubMed  Google Scholar 

  40. Marras TK, Gutierrez C, Chan CK. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest. 2000;118:1339–43.

    Article  CAS  PubMed  Google Scholar 

  41. Arnold FW, Ramirez JA, McDonald LC, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest. 2003;124:121–4.

    Article  PubMed  Google Scholar 

  42. Hu J, Shang H, Li J, Zhang J, Zhang L, Zhang B. Xuebijing injection for sepsis: a comprehensive review. Med J Chin Peoples Liberation Army. 2010;35:9–12.

    Google Scholar 

  43. Xie F, Huang Q. Literature analysis of adverse reactions of Xuebijing injection [in Chinese]. Strait Pharm J. 2013;1:283–4.

    Google Scholar 

Download references

Acknowledgments

This work was supported by Tianjin University “Innovation Team Training Program” (Clinical Evaluation of Traditional Chinese Medicine Innovation Team [TD12-5032]) and Tianjin Chase Sun Pharmaceutical Co., Ltd.

Author information

Authors and Affiliations

  1. Tianjin University of Traditional Chinese Medicine, 312 Anshanxi Road, Nankai District, Tianjin, 300193, China

    Ping Wang, Zhi Liu, Hui Wang, Wenke Zheng, Jingbo Zhai, Ming Ren & Hongcai Shang

  2. Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai Institute of Respiratory Medicine, Shanghai, 200032, China

    Yuanlin Song & Chunxue Bai

  3. Tianjin Chase Sun Pharmaceutical Co. Ltd, 20 Quanfa Road, Tianjin Wuqing Development Area, Tianjin, 300170, China

    Si Liu & Zhiqiao Feng

  4. Peking University Clinical Research Institute, 38 Xueyuan Road, Haidian District, Beijing, 100191, China

    Chen Yao

  5. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Haiyuncang Lane, Dongcheng District, Beijing, 100700, China

    Hongcai Shang

Authors
  1. Ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuanlin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenke Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Si Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhiqiao Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jingbo Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chen Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ming Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chunxue Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hongcai Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chunxue Bai or Hongcai Shang.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HCS sponsored the study and designed this protocol. CXB is the primary supervisor and participated in the design of this protocol. PW drafted the manuscript. YLS helped PW draft and revise the manuscript. HW, WKZ and MR participated in the design of the protocol and are responsible for trial management. ZL, JBZ and CY are involved in the data collection and monitoring of the study. SL and ZQF are supervising this study and participated in revising the manuscript. All authors read and approved the final manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, P., Song, Y., Liu, Z. et al. Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial. Trials 17, 142 (2016). https://doi.org/10.1186/s13063-016-1282-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13063-016-1282-8

Keywords

Trials

ISSN: 1745-6215